First, although consistent funding for medications extended the survival of ALK + NSCLC patients, the limited follow-up duration of the INSPIRE trial required the use of PSM to fit and extrapolate for PFS and OS for data beyond the recorded trial timeframe. Here, ALK is linked to non-small cell lung carcinoma.